Jones Financial Companies
AVIR icon

Jones Financial Companies’s Atea Pharmaceuticals AVIR Stock Holding History

Jones Financial Companies’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-207
Closed -$1.06K – 4979
2026
Q1 		$1.06K Hold
207
– – ﹤0.01% 4335
2025
Q4 		$739 Hold
207
– – ﹤0.01% 4089
2025
Q3 		$607 Hold
207
– – ﹤0.01% 4000
2025
Q2 		$714 Hold
207
– – ﹤0.01% 3734
2025
Q1 		$607 Hold
207
– – ﹤0.01% 3490
2024
Q4 		$693 Hold
207
– – ﹤0.01% 3196
2024
Q3 		$712 Hold
207
– – ﹤0.01% 2854
2024
Q2 		$685 Buy
+207
New +$772 ﹤0.01% 2318

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jones Financial Companies's AVIR Position: Q2 2026 in Review

Jones Financial Companies sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 207 shares — an estimated $1.06K sold.

Jones Financial Companies first reported a position in AVIR in Q2 2024 and held it in 8 quarters. The position peaked at $1.06K in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Jones Financial Companies reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jones Financial Companies sold 207 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.06K.
  • Jones Financial Companies first reported a position in Atea Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • Jones Financial Companies's Atea Pharmaceuticals position peaked at $1.06K in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.